Expectations for AI in healthcare, particularly biopharma and diagnostics, have been high for several years now. New partnerships and acquisitions may…
McAlinden Research PartnersJanuary 17, 2023
Three pharma giants are in the running to purchase Horizon Therapeutics in what will likely be a larger deal than…
McAlinden Research PartnersDecember 1, 2022
Mergers and Acquisitions in the biopharma space continue to heat up, fueling a significant increase in large deals through the first 9…
McAlinden Research PartnersOctober 19, 2022
M&A activity is picking up among pharmaceutical firms with large cash balances. Pfizer and Amgen have each closed a multi-billion…
McAlinden Research PartnersAugust 9, 2022
Pharma giants Pfizer and Moderna just secured multi-billion dollar deals to supply the US government with more than 170 million…
McAlinden Research PartnersAugust 1, 2022
Last year marked one of the least active years for biopharma merger and acquisition (M&A) activity in a decade. The first…
McAlinden Research PartnersJuly 14, 2022
2021 marked another successful year for MRP’s themes, as 16 of 21 themes we closed throughout the year outperformed the…
McAlinden Research PartnersJuly 6, 2022
Throughout the past few months, MRP has highlighted significant cash balances among many biopharmaceutical giants. Though hundreds of billions of dollars…
McAlinden Research PartnersJune 14, 2022
